Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony
S. Marucci, President and Chief Executive Officer of Celldex
Therapeutics, Inc., will present at the BioCentury NewsMakers in the
Biotech Industry Conference on
Friday, October 21st, at 2:00 p.m.
EDT in New York City.
A live webcast of the presentation will be available on the
"Presentations” page of the "Investors” section of Celldex’s website at http://www.celldextherapeutics.com
and will be archived for 30 days following the event.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination
immunotherapy company. Celldex has a pipeline of drug candidates in
development for the treatment of cancer and other difficult-to-treat
diseases based on its antibody focused Precision Targeted Immunotherapy
(PTI) Platform. The PTI Platform is a complementary portfolio of
monoclonal antibodies, antibody-targeted vaccines and immunomodulators
used in optimal combinations to create novel disease-specific drug
candidates. For more information, please visit http://www.celldextherapeutics.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995:
This release contains "forward-looking
statements” made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, including those related to the
Company’s strategic focus and the future development and
commercialization (by Celldex and others) of rindopepimut (CDX-110),
CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127,
Belinostat and other products. Forward-looking statements reflect
management's current knowledge, assumptions, judgment and expectations
regarding future performance or events. Although management believes
that the expectations reflected in such statements are reasonable, they
give no assurance that such expectations will prove to be correct and
you should be aware that actual results could differ materially from
those contained in the forward-looking statements. Forward-looking
statements are subject to a number of risks and uncertainties,
including, but not limited to, our ability to obtain additional capital
on acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials that we plan to
initiate in 2011; our ability to adapt APC Targeting TechnologyTM
to develop new, safe and effective vaccines against oncology and
infectious disease indications; our ability to successfully complete
product research and further development of our programs; the
uncertainties inherent in clinical testing; our limited experience in
bringing programs through Phase 3 clinical trials; our ability to manage
research and development efforts for multiple products at varying stages
of development; the timing, cost and uncertainty of obtaining regulatory
approvals; the failure of the market for the Company's programs to
continue to develop; our limited cash reserves and our ability to obtain
additional capital on acceptable terms, or at all; our ability to
protect the Company’s intellectual property; the loss of any executive
officers or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect the
Company’s products; and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission, including
the Company's Form 10-K for the fiscal year ended December 31, 2010,
and its Forms 10-Q and 8-K.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place undue
reliance on any forward-looking statements, which speak only as of the
date of this release. We have no obligation, and expressly disclaim any
obligation, to update, revise or correct any of the forward-looking
statements, whether as a result of new information, future events or
otherwise.
